...- Select advanced or metastatic solid tumor that is likely to express CLDN18.2 such as gastric/GEJ, pancreatic and esophageal cancer...

...Subjects with locally advanced unresectable or metastatic malignant solid tumors confirmed by histology and/or cytology and CLDN 18.2 positive expression in the tumor tissue confirmed by the central laboratory: dose-escalation phase defined as IHC ≥ 1+ by central laboratory IHC assay; dose-expansion phase and extension cohort studies defined as CLDN18.2 expression in ≥ 40% of tumor cells, the IHC ≥ 2+); 4....

EO-3021 is internalized in claudin 18.2-expressing cells as well as demonstrates cell killing across a range of cancer cell lines with low (IC50 = 228 ng/ml), medium (IC50 = 7 ng/ml), and high levels of claudin 18.2 (IC50 = 28 ng/ml) expression...EO-3021 demonstrates tumor regressions with a single dose across low, medium, and high claudin 18.2-expressing in vivo models derived from pancreatic (9 mg/kg), gastric (2 mg/kg), and lung cancers (8 mg/kg), respectively.

Elevation Oncology, Inc...presenting preclinical proof-of-concept data and highlighting a clinical case study in Claudin 18.2-expressing cancers for the company's lead candidate, EO-3021...EO-3021 demonstrated anti-tumor activity in preclinical xenograft models of pancreatic and gastric cancers expressing varying levels of Claudin 18.2.

EO-3021 demonstrated profound in vivo antitumor activity and outperformed SOC in gastric, pancreatic, and lung cancer models. Results from in vitro and in vivo studies highlight the promising therapeutic potential of EO-3021/SYSA1801 for patients with CLDN18.2-expressing cancers.